Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial

John F. Smyth, A. Bowman, Timothy Perren, +4

Annals of Oncology

MedicineCancer ManagementPharmacologyClinical TrialsGynecology +6

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)

Robert E. Coleman, Michelle Collinson, Walter M. Gregory, +20

Journal of bone oncology

Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

Chris Twelves, Klaas Hoekman, A. Bowman, +11

European Journal of Cancer

MedicinePharmacologySolid TumoursPharmacokinetic StudyPharmacotherapy +4

TELEMAM: A cluster randomised trial to assess the use of telemedicine in multi-disciplinary breast cancer decision making

I.H. Kunkler, R.J. Prescott, R.J. Lee, +13

European Journal of Cancer

NursingMedical Decision MakingHealth PolicyClinical Decision-makingTelemedicine +9

Prognostic Significance of CA 125 and TPS Levels after 3 Chemotherapy Courses in Ovarian Cancer Patients

A. van Dalen, Judith Favier, Alexander Burges, +14

Gynecologic Oncology

Ca 125MedicineGynecologyPathologyTps Levels +6

A phase II study of ifosfamide in children with recurrent solid tumours

CR Pinkerton, Henry C. Rogers, C. Andrew James, +4

Cancer Chemotherapy and Pharmacology

Recurrent Solid TumoursSurgical OncologyTumoral PathologyMedicineMetronomic Therapy +6

Hepatopathy-thrombocytopenia syndrome--a complication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Childrens Cancer Study Group.

June Raine, A. Bowman, Karl Wallendszus, +1

Journal of Clinical Oncology

ThrombosisOncologyHepatologyPediatric HematologyLiver Physiology +13

Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC)

Mark Verrill, J. Lee, David Cameron, +7

Journal of Clinical Oncology

Breast OncologyTotal DoseWeekly PaclitaxelPharmacotherapyPre-clinical Pharmacology +19

Exemestane in metastatic breast cancer: Effective therapy after third-generation non-steroidal aromatase inhibitor failure

Nicola Steele, Jamal Zekri, Robert E. Coleman, +7

The Breast

Metastatic Breast CancerOncologyBreast OncologyMedicineBreast Cancer +7

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly

L. Dawson, Duncan I. Jodrell, A. Bowman, +5

European Journal of Cancer

Pharmaceutical ScienceNovel Anthracenedione AnaloguePharmacologyClinical PhasePharmacotherapy +5